Neoplasm check

18 rows removed

Jev checkDataset build

Every extracted row gets this yes/no question. Rows below 0.5 are removed from the dataset, except AL amyloidosis, which WHO-HAEM5 classifies with the plasma cell neoplasms.

Question the Jev check answers

Does THIS ROW treat a neoplasm? Yes: a malignant or benign tumour, leukaemia, lymphoma, myeloma, myelodysplastic or myeloproliferative neoplasm No: a non-neoplastic disease, e.g. pulmonary fibrosis, graft-versus-host disease, an overgrowth syndrome, an infection

Removed rows (18)

Product	Tumour type (extracted)	P(neoplasm)	Label sentence
Votubia Everolimus	refractory seizures associated with tuberous sclerosis complex	0.06	Votubia is indicated as adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with TSC.
Ofev Nintedanib	idiopathic pulmonary fibrosis	0.02	Ofev is indicated in adults for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
MabThera Rituximab	rheumatoid arthritis	0.03	MabThera in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.
MabThera Rituximab	granulomatosis with polyangiitis (Wegener’s)	0.04	MabThera, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).
MabThera Rituximab	microscopic polyangiitis	0.03	MabThera, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).
MabThera Rituximab	granulomatosis with polyangiitis (Wegener’s)	0.04	MabThera, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged 2 to less than 18 years old) with severe, active GPA (Wegener’s) and MPA.
MabThera Rituximab	microscopic polyangiitis	0.04	MabThera, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged 2 to less than 18 years old) with severe, active GPA (Wegener’s) and MPA.
MabThera Rituximab	pemphigus vulgaris	0.05	MabThera is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (PV).
Ruxolitinib Viatris Ruxolitinib hemifumarate	acute graft versus host disease	0.05	Ruxolitinib Viatris is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).
Ruxolitinib Viatris Ruxolitinib hemifumarate	chronic graft versus host disease	0.05	Ruxolitinib Viatris is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).
Pegasys Peginterferon alfa-2a	chronic hepatitis B	0.03	Pegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1).
Pegasys Peginterferon alfa-2a	chronic hepatitis B	0.03	Pegasys is indicated for the treatment of HBeAg-positive CHB in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.
Pegasys Peginterferon alfa-2a	chronic hepatitis C	0.03	Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease (see sections 4.2, 4.4 and 5.1).
Pegasys Peginterferon alfa-2a	chronic hepatitis C	0.03	Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA.
Vijoice Alpelisib	PIK3CA-related overgrowth spectrum	0.08	Treatment of adult and paediatric patients aged 2 years and older with severe or life-threatening manifestations of PIK3CA-related overgrowth spectrum (PROS)
Gazyvaro Obinutuzumab	lupus nephritis	0.04	Gazyvaro in combination with mycophenolate mofetil (MMF) is indicated for the treatment of adult patients with active Class III or IV, with or without concomitant Class V, lupus nephritis (LN).
Jakavi Ruxolitinib	acute graft versus host disease	0.06	Jakavi is indicated for the treatment of adults and paediatric patients aged 28 days and older with acute graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).
Jakavi Ruxolitinib	chronic graft versus host disease	0.06	Jakavi is indicated for the treatment of adults and paediatric patients aged 6 months and older with chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).